> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – July/August 2015

Loading EJC News Focus video

Clinical trials of MTH1 inhibitors 'ready to go' in many cancer types

Specific inhibition of the MTH1 enzyme could be a means of treating all types of cancer, according to Thomas Helleday (Karolinska Institut, Stockholm). Clinical trials of the first in this new class of drugs – MTH1 inhibitors – could start this year.

The MTH1 enzyme normally prevents damaged nucleotides from being incorporated into a cell's DNA and is required for the survival of cancer cells. It is non-essential in normal cells.

Research into this exciting new class of drugs is being conducted through open innovation, an approach which is well-known in pure science but rarely seen in pharmaceutical development. Here, Thomas Helleday outlines to Helen Saul the progress so far, and the possibilities for the future.